None listed
Conditions
Interventions
Intake two tablets of test food a day, for twelve weeks.
Intake two tablets of control food a day, for twelve weeks.
Sponsors
CPCC Company Limited
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) Females who aged between 20 to 59 when informed consent. (2) Females whose hemoglobin levels at preliminary test are less than 12.0g/L and whose serum ferritin levels are 15ng/mL. (3) Subjects who receive enough explain of the test, who deeply understanding of the test, and who obtain own consent to participate the test.
Exclusion criteria
Exclusion criteria: (1) Females who are received medical treatment due to anemia symptom. (2) Females who have dysmenorrhea. (3) Females who menopaused. (4) Females who have extreme unbalanced diet. (5) Subjects who having medicine, quasi-drug, Food for Specified Health Uses (FOSHU), functional indication food, supplement and/or health food within three months before starting consumption of test food. (6) Subjects who have excess meal regulation, excess diet planning and /or excess irregular meal cycle. (7) Females who are pregnant or lactating, and females who could become pregnant or lactating during test period. (8) Subjects who have previous and/or current medical history of serious disease (e.g., heart, liver, kidney, digestive organ). (9) Subjects who excessive alcohol intake. (10) Subjects who have previous medical history of drug and/or food allergy. (11) Subjects who are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests. (12) Subjects who are intolerant to lactose (13) Subjects who donated over 200mL blood and/or blood components within the last one month to the current study. (14) Females who donated over 400mL blood and/or blood components within the last four month to the current study. (15) Females who will be collected over 800mL blood and/or blood components when, the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. (16) Others who have been determined ineligible by principal investigator or sub-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin level | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum ferritin level Mean corpuscular volume (MCV) Reticulocyte count Total iron binding capacity (TIBC) Red blood cells level (RBC) Mean corpuscular hemoglobin (MCH) Mean corpuscular hemoglobin concentration (MCHC) Hematocrit Serum iron level Serum folic acid level Serum vitamin B12 level Questionnaire of anemia subjective symptoms Questionnaire of QOL Incidence of adverse events and side effects | — |
Countries
Japan
Contacts
Public ContactMakoto Ichinohe
CPCC Company Limited Planning & Sales Department
Outcome results
None listed